Voyager Therapeutics stock soars on AbbVie pact worth potentially $1 billion

Shares of Voyager Therapeutics Inc. VYGR, +17.78% ran up 14.2% in premarket trade Friday, after the gene therapy company and AbbVie Inc. ABBV, +0.24% announced a collaboration to develop antibodies to treat Parkinson’s disease. AbbVie’s stock was still inactive ahead of the open. Under terms of the collaboration, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential milestone payments and royalties. Voyager is also eligible to earn up to a total of $500 million in commercial milestones. Voyager’s stock has lost 10% over the past three months, while AbbVie shares have declined 8.6% and the S&P 500 SPX, +0.41% has gained 4.7%.

Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.